Melanoma Molecular Maps Projects



Title: Drug resistance molecules in melanoma
Legend: This is an archive of molecules involved in melanoma resistance to therapy. Data refer to human melanoma, unless otherwise specified. REFERENCES: [1] La Porta CA, Curr Med Chem 2007, 14:387-91. [2] Koon HB et al, Expert Rev Anticancer Ther 2007, 7:79-88. [3] Soengas MS et al, Oncogene 2003, 22:3138-51. [4] Eberle J et al, Drug Resist Updat 2007, 10:218-34. [5] Lorigan P, Exp Dermatol 2008, 17:383-94 . CITED MOLECULES: ABCB5, ABCC1 (ATP binding cassette subfamily C member 1; multidrug resistance protein 1 [MRP1]), AKT (PKB), ARC, ASNA1 (arsA arsenite transporter ATP-binding homolog 1), ATF2 (activating transcription factor 2), Autotaxin, B7H1 (programmed cell death 1 ligand 1 [PDL1], CD274), Bcl-2 (B cell CLL/lymphoma 2), Bcl-XL (BCL2-like 1), bFGF (basic fibroblast growth factor), BRAF (v-Raf viral oncogene homolog B1), Calpain (CAPN), Clusterin, c-Myc (v-myc myelocytomatosis viral oncogene homolog), CRAF (Raf-1), CREB (cAMP response element binding protein), CTLA4 (cytotoxic T lymphocyte associated protein 4), Delta40p53 (p53 isoform), DFNA5 (deafness, autosomal dominant 5 [ICERE1]), DNMT1 (DNA methyltransferase 1), ERK1 (mitogen-activated protein kinase 3, MAPK3), ERK2 (MAPK1), Farnesyl transferase, FLIP (FLICE [caspase-8] inhibitory protein), Focal adhesion kinase (FAK), GADD45a (growth arrest and DNA damage inducible alpha), Galectin-1 (lectin galactoside-binding soluble 1), gammaGT (gamma glutamyl transferase), GRP78 (glucose regulated protein 78), GSH (glutathione), GSK3 (glycogen synthase kinase 3), GSTM1 (glutathione S-transferase M1), GSTP1 (glutathione S-transferase P1), HDAC (histone deacetylase), HMG-CoA reductase, HSP27 (heat shock protein 27), HSP70, HSP90, hTERT (human telomerase), Hypoxia, IGF1 (insulin like growth factor 1), IGF1R (IGF1 receptor), IKK beta (IkB [inhibitor of NFkB] kinase subunit beta), IL-8 (interleukin-8), INDO (indoleamine 2,3 dioxygenase), Integrin aVb3, Livin (baculoviral IAP repeat containing 7, BIRC7 [ML-IAP, KIAP]), Mcl-1 (myeloid cell leukemia sequence 1), MEK1 (MAP2K1), MEK2 (MAP2K2), MGMT (O6-methylguanine-DNA methyltransferase; alkyl guanine transferase [AGT]), MITF (microphthalmia transcription factor), MMP (matrix metalloproteinase), MnSOD (manganese superoxide dismutase, SOD2), mTOR (mammalian target of rapamycin), MUC4 (mucin 4, cell surface associated), NFkB (nuclear factor kappa B), NG2 (melanoma proteoglycan, MPG), NOS (nitric oxide synthase), PAF (platelet-activating factor), PARP1 (poly [ADP-ribose] polymerase family member 1), PAX3 (paired box protein 3), PI3K (phosphatidylinositol-3-kinase), PKC epsilon (protein kinase C epsilon), PRAS40 (Akt1 substrate 1), Proteasome, ROS (reactive oxygen species), RSK1 (ribosomal S6 kinase [RS6K] 90 kDa), SLUG (SNAIL homolog), SOCS3 (suppressor of cytokine signaling 3), STAT1 (signal transducer and activator of transcription 1), STAT3, STAT5, Survivin (BIRC5), Thioredoxin (TXN), Thioredoxin reductase (TXNR), Thrombin, TOP2A (topoisomerase II alpha), TRAF2 (TNF receptor-associated factor 2), Tubulin beta 3, TYRP2 (tyrosine related protein 2 [TRP2], dopachrome tautomerase [DCT]), Ubc9 (ubiquitin-conjugating enzyme E2), XIAP (X-linked inhibitor of apoptosis), YB-1 (Y box binding protein 1, YBX1).
Author: The MMMP Team (update: January 2009)

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

NCBI's Disclaimer and Copyright notice